Emma Betts' legacy will live on

Emma Betts' legacy will live on

17 May 2019

The inaugural recipient of the Emma Betts PhD Scholarship is Jordan Conway.

Jordan currently works full-time at Melanoma Institute Australia, and will step back from his role as Project Officer/Research Assistant when he begins his PhD in July.

“I’m the age Emma was when she passed away. It almost feels unfair, that she has to not be here for me to be able to do this. But I will use this opportunity to push as hard as I can to reach our collective goal of zero deaths from melanoma.”

JORDAN’S STORY

Jordan’s journey to his PhD wasn’t straightforward.

He always found biology fascinating, and after doing a nursing course in high school he decided that helping people was what he wanted to do. He did medical science at university aiming to continue on to medicine to become a doctor. But his curiosity got the better of him.

“During uni, I noticed that all the greatest leaps forward were because of research and I loved the idea that I could both help people and be academically and intellectually challenged at the same time.”

He applied to do an Honours project after his undergraduate degree finished. After a year of 48-hour stints in the lab and a 15,000-word thesis on cells in a petri dish, some of the glamour of the lab life wore away. The lack of a tangible, real-world outcome and loss of a direct link to people made Jordan question whether research was for him. He decided to take some time working before he chose medicine or research.

Jordan came on board at Melanoma Institute Australia in 2017 as a Biospecimen Bank Officer at Westmead Hospital, where he worked with patients who generously donate their tissue and blood to research at MIA.

I saw so many patients and formed relationships with many of them. I sat in on their appointments, I spoke with them while they were undergoing treatment – I even held a patient’s hand during a biopsy. I got to see the incredible successes of melanoma treatment, only to have other patients I had seen almost every week suddenly no longer return to clinic because their treatments weren’t working. I cried when one patient was told to go home and get his affairs in order over Christmas.

“I became desperate to do more.”

When a position opened in MIA’s translational research group, Jordan jumped at the chance. He was now tasked with assisting all of the research projects by combing through patient data to select the best samples for research. Being exposed to some of the world-leaders in melanoma research rubbed off on him.

​​​​​​JORDAN’S PHD

Spending time in the unique, multidisciplinary team that is the translational research group, Jordan realised that the research at MIA was especially patient-focused – exactly the research he had been drawn to at uni. Inspired by conversations with one of MIA’s clinicians-turned-researchers Dr Ines Da Silva, Jordan found a project idea that he wanted to make his own.

One person every five hours will die from melanoma in Australia. It is the most common cancer in young Australians aged 15–39 years old. While 90% of people with melanoma are able to be cured by having the primary melanoma  removed through surgery, in the other 10% of cases, life-threatening spread will have already occurred.

Over the past five years, the use of surgery, targeted therapies and immunotherapies have significantly extended life expectancy in people with advanced disease (where the melanoma has spread to other organs). In a recent MIA-led trial, researchers have made a major breakthrough by tripling the life expectancy for some advanced melanoma patients. However, up to 50% of patients are either innately resistant to current treatments or develop acquired resistance throughout the course of their treatments. One group of these resistant patients are those who have developed metastatic disease to their liver.

Jordan’s research will look at mechanisms of resistance to immunotherapy, specifically in melanoma patients with liver metastases. Along with other members of the translational research group, he wants to know why the liver seems to be the gatekeeper of resistance. He aims to determine if it is the site of metastasis that creates a poor systemic response, or something within the biology of the tumour that causes the melanoma to metastasise to the liver and make it resistant to therapy. He is excited by the clinical relevance of this project – in clinical settings, patients with liver metastases tend to have a worse outcome on treatment. Jordan is also hoping that, like immunotherapy, his research could translate to other cancers.

I can’t think of a better place to do my PhD. Not only am I able to use the amazing resources that MIA has – like the biobank and the research database – but the translational research group has so many people I’m inspired by who are all committed to making a difference, like MIA’s Co-Medical Directors Professor Georgina Long and Professor Richard Scolyer.

I’m doing my PhD because I believe that every patient deserves the best opportunity to survive this harrowing disease and right now, there are patients that aren’t surviving. I want to know why, but more importantly, do everything in my power to make sure that this isn’t the case forever. Advanced melanoma used to be a death sentence, and through the determination of the researchers around me here at Melanoma Institut Australia, it isn’t anymore. Our mission is zero deaths from melanoma, and I am excited to potentially play a part in achieving that.

“I want to follow in their footsteps and utilise their knowledge and the resources they have available to ensure that the patients that aren’t responding get to spend more time with their families. It’s always about the patients, and I have had the honour of meeting so many of them.”

JORDAN IS DETERMINED TO HONOUR EMMA’S LEGACY

When applying for his PhD, Jordan realised that without a scholarship, he wouldn’t be able to give all of his time to his research. No stranger to hard work, Jordan thought about getting a night or weekend job to ensure he could pay for his day-to-day expenses – his phone, his food and his transport to and from the lab each day. Then, the Emma Betts PhD Scholarship came along.

During her illness, Emma was an ardent supporter of Melanoma Institute Australia. She knew research was the key to saving lives from melanoma, and she selflessly devoted her time to raising awareness and encouraging Australians to support research. She started  Through the Looking Glass, which quickly became an annual event. Two years after her passing, it is still run by her parents, Leon and Tamra, who are determined to continue Emma’s legacy. Melanoma Institute Australia is delighted to honour Emma by creating the Emma Betts PhD Scholarship, to ensure up and coming young researchers with the same vision as Emma, are supported in their work.

Jordan, who followed Emma’s blog and had long heard of Emma’s dream for a cure for melanoma, is a fitting inaugural recipient of the Emma Betts PhD Scholarship.    

“I’m so grateful to receive the inaugural Emma Betts PhD Scholarship. This scholarship means that I can devote the next three and a half years of my life to this research. I can focus day-in and day-out on trying to solve this problem that affects far too many people.”

It’s fitting that Emma’s legacy is allowing a young person much like her to fulfil their dreams.

“I’m the age Emma was when she passed away. It almost feels unfair, that she has to not be here for me to be able to do this. But I will use this opportunity to push as hard as I can to reach our collective goal of zero deaths from melanoma.”

Jordan will be guest of honour at the Through the Looking Glass event on Saturday 18th May in Brisbane. Emma’s parents are urging supporters to purchase tickets as soon as possible, to ensure Emma’s legacy can live on.

International collaboration the key to increasing survival
24 Oct 2018

International collaboration the key to increasing survival

"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration
23 Oct 2018

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.

Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
11 Oct 2018

Monthly dose of immunotherapy allows flexibility for patients undergoing treatment

A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.

Australia's best minds in melanoma research converge on Melbourne
08 Oct 2018

Australia's best minds in melanoma research converge on Melbourne

The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.

Nobel Prize for novel cancer therapies
04 Oct 2018

Nobel Prize for novel cancer therapies

The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.

World Health Organisation launches 4th edition of Classification of Skin Tumours
31 Aug 2018

World Health Organisation launches 4th edition of Classification of Skin Tumours

The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.

Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
31 Aug 2018

Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal

Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.

Support PBS listing for pembrolizumab
23 Aug 2018

Support PBS listing for pembrolizumab

Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.

World Congress on Cancers of the Skin 2018
17 Aug 2018

World Congress on Cancers of the Skin 2018

The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.

Melanoma Institute Australia welcomes new CEO Matthew Browne
09 Aug 2018

Melanoma Institute Australia welcomes new CEO Matthew Browne

Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).

Melanoma in Practice: Nurse Conference
26 Jul 2018

Melanoma in Practice: Nurse Conference

It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’. 

Reducing the risk of melanoma in young adults
19 Jul 2018

Reducing the risk of melanoma in young adults

A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.

Melanoma Institute Australia launches free e-learning education portal
20 Jun 2018

Melanoma Institute Australia launches free e-learning education portal

Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.

David Day and a lifetime of missed moments
08 Jun 2018

David Day and a lifetime of missed moments

When David lost his life last year, he was 33, with three daughters under six.

Australian melanoma experts share latest breakthroughs with world's best oncologists
06 Jun 2018

Australian melanoma experts share latest breakthroughs with world's best oncologists

ASCO 2018 brings together the world's best in oncology from around the world. 

ASCO 2018 – the important role of clinical trials
06 Jun 2018

ASCO 2018 – the important role of clinical trials

Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.

MIA Scoops Awards at the International Academy of Pathology
04 Jun 2018

MIA Scoops Awards at the International Academy of Pathology

Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology. 

Updated Clinical Guidelines for Melanoma
25 May 2018

Updated Clinical Guidelines for Melanoma

Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.

Melanoma and Marital Status: A Study
11 May 2018

Melanoma and Marital Status: A Study

An American study has discovered a link between early detection and marital status in melanoma diagnosis. 

A weekend in Paris talking all things pathology...
02 May 2018

A weekend in Paris talking all things pathology...

An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.